Literature DB >> 24157242

Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor.

Daniel L Suzman1, Mario A Eisenberger2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24157242      PMCID： PMC4090698          DOI： 10.1016/j.eururo.2013.10.002

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  11 in total

1.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Authors:  Rong Hu; Changxue Lu; Elahe A Mostaghel; Srinivasan Yegnasubramanian; Meltem Gurel; Clare Tannahill; Joanne Edwards; William B Isaacs; Peter S Nelson; Eric Bluemn; Stephen R Plymate; Jun Luo
Journal:  Cancer Res       Date:  2012-06-18       Impact factor: 12.701

4.  Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

Authors:  K L Noonan; S North; R L Bitting; A J Armstrong; S L Ellard; K N Chi
Journal:  Ann Oncol       Date:  2013-04-12       Impact factor: 32.976

5.  Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.

Authors:  Antoine Italiano; Cécile Ortholan; Stéphane Oudard; Damien Pouessel; Gwenaëlle Gravis; Philippe Beuzeboc; Emmanuelle Bompas; Aude Fléchon; Florence Joly; Jean-Marc Ferrero; Karim Fizazi
Journal:  Eur Urol       Date:  2008-08-08       Impact factor: 20.096

6.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

7.  Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.

Authors:  C N Sternberg; J S de Bono; K N Chi; K Fizazi; P Mulders; L Cerbone; M Hirmand; D Forer; H I Scher
Journal:  Ann Oncol       Date:  2014-02       Impact factor: 32.976

8.  Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.

Authors:  Andres Jan Schrader; Martin Boegemann; Carsten-H Ohlmann; Thomas J Schnoeller; Laura-Maria Krabbe; Turkan Hajili; Florian Jentzmik; Michael Stoeckle; Mark Schrader; Edwin Herrmann; Marcus V Cronauer
Journal:  Eur Urol       Date:  2013-07-02       Impact factor: 20.096

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

10.  Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Authors:  J Mezynski; C Pezaro; D Bianchini; A Zivi; S Sandhu; E Thompson; J Hunt; E Sheridan; B Baikady; A Sarvadikar; G Maier; A H M Reid; A Mulick Cassidy; D Olmos; G Attard; J de Bono
Journal:  Ann Oncol       Date:  2012-07-05       Impact factor: 32.976
View more
  3 in total

Review 1.  [Concepts in geriatric uro-oncology].

Authors:  A Manseck; S Manseck; C Körner
Journal:  Urologe A       Date:  2019-04       Impact factor: 0.639

2.  Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors.

Authors:  Elena Verzoni; Paolo Grassi; Raffaele Ratta; Monica Niger; Filippo De Braud; Riccardo Valdagni; Giuseppe Procopio
Journal:  Ther Adv Med Oncol       Date:  2016-07-05       Impact factor: 8.168

3.  Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.

Authors:  Alessia Cavo; Alessandra Rubagotti; Elisa Zanardi; Chiara Fabbroni; Linda Zinoli; Antonio Di Meglio; Eleonora Arboscello; Andrea Bellodi; Paolo Spallarossa; Carlo Cattrini; Carlo Messina; Francesco Boccardo
Journal:  Ther Adv Med Oncol       Date:  2018-01-09       Impact factor: 8.168
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.